ATE215837T1 - Modulation von zellproliferation und wundheilung - Google Patents

Modulation von zellproliferation und wundheilung

Info

Publication number
ATE215837T1
ATE215837T1 AT95941332T AT95941332T ATE215837T1 AT E215837 T1 ATE215837 T1 AT E215837T1 AT 95941332 T AT95941332 T AT 95941332T AT 95941332 T AT95941332 T AT 95941332T AT E215837 T1 ATE215837 T1 AT E215837T1
Authority
AT
Austria
Prior art keywords
cell proliferation
modulation
wound healing
intraocular
drug
Prior art date
Application number
AT95941332T
Other languages
English (en)
Inventor
Peter J Kelleher
Original Assignee
Houston Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Houston Biotechnology filed Critical Houston Biotechnology
Application granted granted Critical
Publication of ATE215837T1 publication Critical patent/ATE215837T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
AT95941332T 1994-10-26 1995-10-24 Modulation von zellproliferation und wundheilung ATE215837T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32936694A 1994-10-26 1994-10-26
US08/483,795 US5618553A (en) 1994-10-26 1995-06-07 Methods and compositions for the modulation of cell proliferation and wound healing
PCT/US1995/013715 WO1996013286A2 (en) 1994-10-26 1995-10-24 Modulation of cell proliferation and wound healing

Publications (1)

Publication Number Publication Date
ATE215837T1 true ATE215837T1 (de) 2002-04-15

Family

ID=26986758

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941332T ATE215837T1 (de) 1994-10-26 1995-10-24 Modulation von zellproliferation und wundheilung

Country Status (9)

Country Link
US (2) US6063116A (de)
EP (1) EP0788383B1 (de)
JP (1) JP2000513951A (de)
CN (1) CN1092990C (de)
AT (1) ATE215837T1 (de)
AU (1) AU710144B2 (de)
DE (1) DE69526363D1 (de)
IL (1) IL115721A (de)
WO (1) WO1996013286A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6186148B1 (en) 1998-02-04 2001-02-13 Kiyoshi Okada Prevention of posterior capsular opacification
US20050119601A9 (en) * 1999-04-26 2005-06-02 Lynch Mary G. Shunt device and method for treating glaucoma
US6464724B1 (en) 1999-04-26 2002-10-15 Gmp Vision Solutions, Inc. Stent device and method for treating glaucoma
DE19955836C1 (de) * 1999-11-19 2001-05-17 Norbert Hampp Ophthalmologisches Implantat
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US7708711B2 (en) * 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US20050277864A1 (en) * 2000-04-14 2005-12-15 David Haffner Injectable gel implant for glaucoma treatment
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US6599526B2 (en) * 2000-08-18 2003-07-29 The University Of North Texas Health Science Center At Fort Worth Pericardial anti-adhesion patch
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
EP1339438B1 (de) * 2000-11-29 2005-10-19 Allergan Inc. Verhinderung von transplantatabstossung im auge
WO2002055058A2 (en) * 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US20060029955A1 (en) * 2001-03-24 2006-02-09 Antonio Guia High-density ion transport measurement biochip devices and methods
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6981958B1 (en) 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
WO2002080811A2 (en) 2001-04-07 2002-10-17 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US7488303B1 (en) 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US7678065B2 (en) * 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
US7094225B2 (en) * 2001-05-03 2006-08-22 Glaukos Corporation Medical device and methods of use of glaucoma treatment
US6973718B2 (en) * 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
US6827250B2 (en) * 2001-06-28 2004-12-07 Microchips, Inc. Methods for hermetically sealing microchip reservoir devices
US7331984B2 (en) * 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US9301875B2 (en) * 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
AU2003222668A1 (en) * 2002-04-25 2003-11-10 Rapidheal, Inc. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
SI2561860T1 (en) * 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
ATE424187T1 (de) * 2002-07-15 2009-03-15 Alcon Inc Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
EP1542739B1 (de) * 2002-09-26 2008-12-10 Angiotech International Ag Perivaskuläre hüllen
CA2509382A1 (en) * 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
US7544368B2 (en) 2002-12-20 2009-06-09 Life Spring Biotech Co., Ltd. Structure for modulating intraocular pressure
US20040121943A1 (en) * 2002-12-20 2004-06-24 Wei-Cherng Hsu Drug-free biodegradable 3D porous collagen-glycosaminoglycan scaffold
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PT1610791E (pt) * 2003-03-31 2011-05-23 Titan Pharmaceuticals Inc Dispositivo polim?rico implant?vel para liberta??o sustentada de agonista da dopamina
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005049105A2 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
EP1696831B1 (de) * 2003-12-05 2014-01-15 Innolene LLC Verfahren zum herstellen einer refraktiven okularlinse
US20050250788A1 (en) * 2004-01-30 2005-11-10 Hosheng Tu Aqueous outflow enhancement with vasodilated aqueous cavity
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
WO2006034383A1 (en) * 2004-09-21 2006-03-30 Advanced Medical Optics, Inc. Viscoelastic solution or gel formulation, and methods of treating a body site with the same
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
EP1890652B1 (de) * 2005-05-13 2017-08-02 Akkolens International B.V. Künstliche intraokularlinse für durch die iris bewirkte akkomodation
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008061043A2 (en) 2006-11-10 2008-05-22 Glaukos Corporation Uveoscleral shunt and methods for implanting same
JP4957258B2 (ja) * 2007-01-15 2012-06-20 富士通株式会社 歩数計数装置および歩数計数方法
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
NZ592645A (en) * 2008-11-20 2013-01-25 Insight Innovations Llc Biocompatible biodegradable intraocular implant system
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (de) 2009-05-18 2018-01-10 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
WO2010147962A1 (en) 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
EP3069612A3 (de) 2009-06-15 2016-10-19 Encore Health, LLC Dithiolverbindungen, derivate davon und verwendungen davon
US8961600B2 (en) * 2009-06-25 2015-02-24 Optonol Ltd. Method of using a fiber matrix for maintaining space in soft tissues
US20110105996A1 (en) * 2009-10-16 2011-05-05 Northwestern University Methods for scar prevention
US20110218606A1 (en) * 2010-03-02 2011-09-08 Medtronic Vascular, Inc. Methods for Stabilizing Femoral Vessels
EP2654715B1 (de) 2010-11-24 2017-01-25 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
US9186243B2 (en) * 2011-05-31 2015-11-17 Novartis Ag Accommodative intraocular lens and method of implantation
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
GB2501943B (en) * 2012-05-10 2020-09-23 Zeiss Carl Meditec Ag Ophthalmic viscoelastic device
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
CA2941518A1 (en) 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
JP7579594B2 (ja) 2020-05-15 2024-11-08 アイフロー・インコーポレーテッド 哺乳類の眼の従来の房水排出路内の移植物のための方法及び装置

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4097657A (en) * 1976-04-07 1978-06-27 Diamond Shamrock Corporation Surface-treated soft contact lenses
US4170043A (en) * 1977-11-30 1979-10-09 American Hospital Supply Corporation Coated intraocular lens and surgical tool
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
EP0092918B1 (de) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Mittel mit verzögerter Freigabe
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
JPH0641424B2 (ja) * 1984-11-06 1994-06-01 ライオン株式会社 う蝕予防剤
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
DE3783211T2 (de) * 1986-11-04 1993-04-29 Baylor College Medicine Zusammensetzungen zur verhuetung sekundaeren grauen stars.
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5080924A (en) * 1989-04-24 1992-01-14 Drexel University Method of making biocompatible, surface modified materials
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
EP0443809A3 (en) * 1990-02-20 1992-04-15 Ioptex Research Inc. Coated intraocular lens and coatings therefor
AU4800593A (en) * 1990-03-06 1995-02-28 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
WO1995003783A1 (en) * 1990-03-06 1995-02-09 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995033492A1 (en) * 1994-06-09 1995-12-14 Houston Biotechnology Incorporated Methods and compositions for modulation of wound healing
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5554187A (en) * 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5728751A (en) * 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces

Also Published As

Publication number Publication date
WO1996013286A3 (en) 1996-06-20
EP0788383A2 (de) 1997-08-13
US6063116A (en) 2000-05-16
IL115721A0 (en) 1996-01-19
CN1179725A (zh) 1998-04-22
US5618553A (en) 1997-04-08
CN1092990C (zh) 2002-10-23
DE69526363D1 (de) 2002-05-16
JP2000513951A (ja) 2000-10-24
AU710144B2 (en) 1999-09-16
EP0788383B1 (de) 2002-04-10
AU4278496A (en) 1996-05-23
WO1996013286A2 (en) 1996-05-09
IL115721A (en) 2000-07-26

Similar Documents

Publication Publication Date Title
ATE215837T1 (de) Modulation von zellproliferation und wundheilung
DK0790823T3 (da) Lægemiddelafgivende kirurgisk implantat eller forbindingsmateriale
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
ES2161229T3 (es) Microesferas bioterapeuticas revestidas con celulas.
DK0696205T3 (da) Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi
EP1659981A4 (de) Prothesenfixiervorrichtung und anwendungsverfahren dafür
DK0590015T3 (da) Sammensætning til vævsbehandling omfattende fibrin eller fibrinogen og bionedbrydelig og bioforligelig polymer
AU5056196A (en) Hydrogel-forming, self-solvating absorbable polyester copolymers and methods for use thereof
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
ATE343983T1 (de) Ophthalmologisches implantat
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DK1069902T3 (da) Anvendelse af phospholipider til fremstilling af et lægemiddel til forebyggelse af adhæsioner
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
Netscher et al. A method for optimizing skin graft healing and outcome of wounds of the penile shaft and scrotum
AR016200A1 (es) El uso de una composicion que comprende uno o mas compuestos que contienen azufre para la fabricacion de un medicamento para aumentar la permeabilidad deltejido corneo humano, y un kit que incluye dicha composicion
Travis Initial Experience Combining Negative Pressure Wound Therapy with Autologous Skin Cell Suspension and Meshed Autografts
UA32660A (uk) Підкладка до дерматомів
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
Hickok et al. What are the legal implications for a physical therapist applying an immediate postoperative rigid dressing, a cast change, or a preparatory plaster of Paris prosthesis to an amputee under the order and supervision of a physician
RU95107940A (ru) Способ хирургического лечения макулодистрофий различного генеза
UA36465A (uk) Спосіб ушивання глибоких і нешироких ран та голка для його здійснення
UA37531A (uk) Спосіб хірургічного лікування глибоких опіків
UA33839A (uk) Спосіб хірургічного лікування проникаючих поранень рогівки ока

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties